肿瘤细胞治疗研究
ALL SOURCES
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
淋巴细胞清除化疗后序贯 ADP-A2AFP TCR T 细胞疗法显示出可控的安全性特征，并在这类既往接受过治疗的患者中呈现出抗肿瘤活性的初步迹象。
Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy.
T细胞受体（TCR）T细胞疗法是一种过继性细胞疗法，将患者细胞工程化以表达靶向特定肿瘤抗原的TCR，然后回输给患者。
Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in m
转基因 TCR 与 CAR 联合，扩展了用于肝细胞癌 T 细胞治疗的 GPC3 靶向受体库。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
